Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCALE KIDS: liraglutide in children with obesity
MOH_2021-01-18_009497Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Dec 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in childhood obesity comparing Liraglutide 3.0 mg with Placebo (2 arms). Primary endpoint: Primary endpoint not reported. Started Dec 2020; status: active, not recruiting.
02
Drugs
03
Conditions
childhood obesity
Beyond the preview
Go deeper on MOH_2021-01-18_009497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-01-18_009497.